Siddhartha Paul is a R & D scientist at ATCC cell system, a subsidiary of ATCC, located in Gaithersburg, Maryland, USA. He received his masters in Biochemistry from University of Mysore, India and Ph.D in Biochemistry from Ruhr University, Bochum, Germany. After his PhD, he joined Dr. Richard Schlegel’s lab, where he focused on understanding HPV pathogenesis in cervical cancer and utilizing conditional reprograming (CR) technology to immortalize cells. He joined ATCC and continued his research on next generation cancer models utilizing newer cutting edge technologies such as 3D organoids, and CR technologies. During this time, he developed a keen interest on exosome research and currently focused on developing new products for exosome research.
Dr. Paul received several awards during his research including best invention award for his PhD thesis work. He is currently a member of American society of cell biology (ASCB) and American association of Cancer research (AACR) and International society for extracellular vesicles (ISEV).